Clinical Report: Study explores adding a low-dose, daily oral chemotherapy for patients with melanoma

Overview

A new clinical trial is investigating the addition of low-dose oral chemotherapy (cyclophosphamide) to standard immunotherapy for melanoma patients who have progressed after first-line treatment.

Background

Melanoma treatment has evolved significantly with the advent of immunotherapy; however, many patients develop resistance to these therapies over time. The exploration of combining traditional chemotherapy with immunotherapy is being studied.

Data Highlights

No numerical data or trial results are provided in the source material.

Key Findings

• The trial is led by Dr. Warren Chow and sponsored by the UC Irvine Anti-Cancer Challenge.
• It focuses on patients who have progressed on first-line immunotherapy for melanoma.
• The study aims to evaluate the efficacy of adding low-dose cyclophosphamide to standard immunotherapy.
• Insights from this trial are expected to be available by ASCO 2027.
• The approach seeks to address the challenge of resistance to immune checkpoint inhibitors.

Clinical Implications

This trial may provide insights into treatment strategies for melanoma patients who have limited options after failing first-line therapies.

Conclusion

The ongoing clinical trial is focused on addressing treatment resistance in melanoma.

Related Resources & Content

1. UCI Health, UCI Health, 2023 -- Study explores adding a low-dose, daily oral chemotherapy for patients with melanoma
2. The ASCO Post — Oral Metronomic Chemotherapy Plus Ultra-Low-Dose Immunotherapy Improves Survival in Advanced Head and Neck Cancer
3. The ASCO Post — Study Suggests Lack of Benefit With the Addition of Immune Checkpoint Inhibition to Chemotherapy in Low PD-L1–Expressing Gastric or Esophageal Adenocarcinoma
4. Stat News — Ultra-low doses could bring costly cancer treatments to more patients in poorer countries
5. the asco post — Four-Drug Induction Regimen Under Study in Advanced Melanoma With BRAF Mutation
6. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0
7. Rechallenge of ipilimumab and nivolumab in advanced melanoma patients after previous ipilimumab-based therapy - PMC
8. Study Details | NCT06771544 | Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma | ClinicalTrials.gov